Scarica l'app Stockscreener
162.80
2.09%
-3.48
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Nigeria
Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands - Sahm
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada
Belite Bio Q2 2026 Earnings Call Transcript - MarketBeat
Belite Bio Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks
Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss - Stock Titan
Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease - Sahm
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
BLTE (NASDAQ: BLTE) files Form 144 for 93,800 ADS sale - Stock Titan
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating - TipRanks
Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook - Investing.com
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - TradingView
HC Wainwright Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - TipRanks
FDA grants priority review for Belite Bio’s Stargardt treatment By Investing.com - Investing.com Nigeria
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) wins FDA priority review for tinlarebant in Stargardt disease - Stock Titan
Belite Bio (BLTE) Short Interest & Short Float | Updated Aug 2026 $BLTE - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Purchases New Shares in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results - markets.businessinsider.com
Renaissance Technologies LLC Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio (BLTE) Expected to Post Quarterly Earnings on Monday - MarketBeat
Perceptive Advisors LLC Has $24.23 Million Stock Position in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
ADAR1 Capital Management LLC Sells 12,959 Shares of Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
(BLTE) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Price to sales forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01 - TradingView
Belite Bio, Inc. Sponsored ADR $BLTE Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - MarketBeat
Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK
Belite Bio stock price target maintained at $200 by H.C. Wainwright By Investing.com - Investing.com Australia
Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com South Africa
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 - The Manila Times
Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
Belite Bio, Inc. ADR (BLTE) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):